Case Studies2025-01-29T09:56:38+01:00

Case Studies

Genialis works with pharma and biopharma, diagnostics companies, and clinical researchers to develop and commercialize RNA Biomarkers

Our expertise extends beyond our proprietary biomarker pipeline. We collaborate with partners to design and execute biomarker programs tailored for specific goals, including:

  • Enhancing translational decision-making

  • Optimizing clinical trial design

  • Developing new assays

  • Improving patient care

A RAS Biomarker for Precise Patient Stratification2025-01-29T11:25:47+01:00

A biopharma company developing an innovative RAS inhibitor turned to Genialis for enhanced patient stratification beyond standard mutation-based approaches—and deeper insights into their drug’s mechanism of action

Approach

  • Pinpoint Pathways
    We collaborated to identify critical biological pathways in solid tumor patients

  • Rapidly Configure the Algorithm
    Leveraging the Genialis™ Supermodel and Genialis™ krasID, we delivered  a proof-of-concept biomarker algorithm tuned to the drug and indication—all in under six weeks

  • Refine with Real-World, Validate on In-Patient Data
    The algorithm was fine-tuned using human datasets and retrospectively validated with Phase 1 clinical results

  • Enable Clinical Deployment
    Our R&D team is now partnering with the company’s diagnostic division to implement the biomarker for clinical trial assay development

Result

Armed with a powerful tool to better understand their drug’s mechanism of action and predict patient response, the biopharma partner successfully integrated an advanced biomarker strategy into their clinical program—accelerating progress toward regulatory approval.

A Custom DDR Biomarker for identifying responders to WEE1 inhibitor2025-02-03T16:18:37+01:00
Debiopharm logo

Debiopharm, a leader in DNA Damage Repair (DDR) therapeutics, is collaborating with Genialis to develop a model aimed at optimizing patient stratification for their DDR-targeting drugs. Historically, the complexity of DDR biology has limited the durability of monotherapies, necessitating patient selection and rational combinations, both requiring accurate and information-rich biomarkers.

Approach

  • Pinpoint Pathways
    We dissected DDR’s complexities to identify critical biological processes and interactions influencing therapy response and resistance

  • Rapidly Configure the Algorithm
    We configured a biomarker algorithm comprising numerous biological modules representing various biologies contributing to DDR therapeutic vulnerability

  • Refine and Validate on In-vivo Data
    Developing a Debiopharm proprietary model using existing translational and clinical data to enhance the biomarker’s predictive power for patient response

  • Explore Clinical Deployment
    Genialis continues to collaborate with Debiopharm to refine the biomarker and explore its potential integration into clinical trials

Result

In early 2025, Genialis announced an extension of its collaboration with Debiopharm to develop a predictive biomarker for WEE1-targeted therapy. Debiopharm’s WEE1 asset is currently in Phase 1 clinical research and is being studied as monotherapy and in multiple combinations in collaboration with international partners.

Teaming Up with PanCan to Transform Pancreatic Cancer Care2025-01-29T11:35:10+01:00
PanCAN logo

Genialis is proud to partner with the Pancreatic Cancer Action Network (PanCAN) to advance biomarker solutions for patients with pancreatic cancer. Through PanCAN’s “Know Your Tumor” program, we analyzed 493 pancreatic adenocarcinoma samples using Genialis krasID.

This large-scale analysis uncovered varying probabilities of response to KRAS inhibitors across multiple patient genotypes (including KRAS G12D and wild-type). These findings highlight how krasID could guide more personalized treatment.

Moving forward, we’re collaborating with PanCAN to refine krasID so clinicians can select the most effective therapies, ultimately improving patient outcomes and quality of life.

Next-Gen Biomarkers Advancing Academic and Clinical Collaborations Around the Globe2025-01-29T11:11:47+01:00
Sidra Medicine logo

Genialis has teamed up with Sidra Medicine to validate biomarkers that predict how patients from the Middle East will respond to gastrointestinal cancer treatments.

Cancer Research Horizons logo

In 2023, Genialis partnered with Cancer Research Horizons (CRH), the innovation arm of Cancer Research UK. CRH provided anonymized, curated datasets with ‘omics and clinical metadata to support the training and validation of Genialis RNA biomarkers.

4baseCare logo

Genialis and 4baseCare are working together to develop biomarkers that predict patient responses to standard-of-care treatments in Asia and the Middle East.

Academia Sinica logo

Genialis and Academia Sinica have launched an NSCLC program to identify the best treatments for early-stage and TKI-resistant patients in East Asia.